|
1
|
McKelvie RS, Moe GW, Cheung A, Costigan J,
et al: The 2011 Canadian Cardiovascular Society heart failure
management guidelines update: focus on sleep apnea, renal
dysfunction, mechanical circulatory support, and palliative care.
Can J Cardiol. 27:319–338. 2011. View Article : Google Scholar
|
|
2
|
Hayashi M, Tsutamoto T, Wada A, et al:
Relationship between transcardiac extraction of aldosterone and
left ventricular remodeling in patients with first acute myocardial
infarction: extracting aldosterone through the heart promotes
ventricular remodeling after acute myocardial infarction. J Am Coll
Cardiol. 38:1375–1382. 2001. View Article : Google Scholar
|
|
3
|
Leopold JA: Aldosterone, mineralocorticoid
receptor activation, and cardiovascular remodeling. Circulation.
124:e466–e468. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Sun Y, Zhang J, Lu L, Chen SS, Quinn MT
and Weber KT: Aldosterone-induced inflammation in the rat heart:
role of oxidative stress. Am J Pathol. 161:1773–1781. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Zannad F, Alla F, Dousset B, Perez A and
Pitt B: Limitation of excessive extracellular matrix turnover may
contribute to survival benefit of spironolactone therapy in
patients with congestive heart failure: insights from the
randomized aldactone evaluation study (RALES). Rales Investigators.
Circulation. 102:2700–2706. 2000. View Article : Google Scholar
|
|
6
|
Pitt B, Ruilope L, Bakris G, et al:
EPHESUS Investigators: 459 Risk/benefit analysis of hyperkalemia in
the eplerenone post-acute myocardial infarction heart failure
efficacy and survival study (EPHESUS). Eur J Heart Fail. 3(Supp l):
1162004.PubMed/NCBI
|
|
7
|
Zannad F, Stough WG, Rossignol P, et al:
Mineralocorticoid receptor antagonists for heart failure with
reduced ejection fraction: integrating evidence into clinical
practice. Eur Heart J. 33:2782–2795. 2012. View Article : Google Scholar
|
|
8
|
Butler J, Ezekowitz JA, Collins SP, et al:
Update on aldosterone antagonists use in heart failure with reduced
left ventricular ejection fraction. Heart Failure Society of
America Guidelines Committee. J Card Fail. 18:265–281. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Zannad F, McMurray JJ, Krum H, et al:
Eplerenone in patients with systolic heart failure and mild
symptoms. N Engl J Med. 364:11–21. 2011. View Article : Google Scholar
|
|
10
|
Bhakta S and Dunlap ME:
Angiotensin-receptor blockers in heart failure: evidence from the
CHARM trial. Cleve Clin J Med. 71:665–673. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Krum H, Carson P, Farsang C, et al: Effect
of valsartan added to background ACE inhibitor therapy in patients
with heart failure: results from Val-HeFT. Eur J Heart Fail.
6:937–945. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Mann DL and Bristow MR: Mechanisms and
models in heart failure: the biomechanical model and beyond.
Circulation. 111:2837–2849. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Stockand JD and Meszaros JG: Aldosterone
stimulates proliferation of cardiac fibroblasts by activating
Ki-RasA and MAPK1/2 signaling. Am J Physiol Heart Circ Physiol.
284:H176–H184. 2003.PubMed/NCBI
|
|
14
|
Chancey AL, Brower GL, Peterson JT and
Janicki JS: Effects of matrix metalloproteinase inhibition on
ventricular remodeling due to volume overload. Circulation.
105:1983–1988. 2002.PubMed/NCBI
|
|
15
|
Michel F, Ambroisine ML, Duriez M,
Delcayre C, Levy BI and Silvestre JS: Aldosterone enhances
ischemia-induced neovascularization through angiotensin
II-dependent pathway. Circulation. 109:1933–1937. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Davis GE, Pintar Allen KA, Salazar R and
Maxwell SA: Matrix metalloproteinase-1 and -9 activation by plasmin
regulates a novel endothelial cell-mediated mechanism of collagen
gel contraction and capillary tube regression in three-dimensional
collagen matrices. J Cell Sci. 114:917–930. 2001.
|
|
17
|
Johnson C, Sung HJ, Lessner SM, Fini ME
and Galis ZS: Matrix metalloproteinase-9 is required for adequate
angiogenic revascularization of ischemic tissues: potential role in
capillary branching. Circ Res. 94:262–268. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Yan L, Moses MA, Huang S and Ingber DE:
Adhesion-dependent control of matrix metalloproteinase-2 activation
in human capillary endothelial cells. J Cell Sci. 113:3979–3987.
2000.PubMed/NCBI
|
|
19
|
Haas TL, Milkiewicz M, Davis SJ, et al:
Matrix metalloproteinase activity is required for activity-induced
angiogenesis in rat skeletal muscle. Am J Physiol Heart Circ
Physiol. 279:H1540–H1547. 2000.PubMed/NCBI
|
|
20
|
Silvestre JS, Heymes C, Oubénaïssa A, et
al: Activation of cardiac aldosterone production in rat myocardial
infarction: effect of angiotensin II receptor blockade and role in
cardiac fibrosis. Circulation. 99:2694–2701. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Drüppel V, Kusche-Vihrog K, Grossmann C,
et al: Long-term application of the aldosterone antagonist
spironolactone prevents stiff endothelial cell syndrome. FASEB J.
27:3652–3659. 2013.PubMed/NCBI
|
